282 results on '"Sailer, Verena"'
Search Results
2. Wissensweitergabe in einer stark wachsenden Organisation – die ZAWI-Treuhand Steuerberatungsgesellschaft als Praxisbeispiel
3. Molekulare Mechanismen der Resistenzentstehung und pathologische Aspekte der Therapieplanung beim Prostatakarzinom
4. Experimental in vitro, ex vivo and in vivo models in prostate cancer research
5. Elevated PSPC1 and KDM5C expression indicates poor prognosis in prostate cancer
6. Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation
7. Azinäres Adenokarzinom der Prostata
8. Adenomyomatöse Prostatahyperplasie
9. Immunhistochemische Aufarbeitung
10. Aktuelles Grading und Befunderstellung
11. Neuroendokrines Prostatakarzinom
12. Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses Its Pro-Oncogenic Effects in Prostate Cancer
13. CEACAM6 Promotes Lung Metastasis via Enhancing Proliferation, Migration and Suppressing Apoptosis of Prostate Cancer Cells.
14. Correlation of Intra-tumoral and Peripheral PD-1/PD-L1 Immunity in Head and Neck Cancer
15. Pathological Assessment of Prostate Cancer
16. FIGURE 1 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
17. Supplementary Figure 1 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
18. Supplementary Data Legends from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
19. Supplementary Table 1 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
20. FIGURE 5 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
21. FIGURE 3 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
22. Supplementary Figure 3 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
23. FIGURE 4 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
24. Supplementary Figure 2 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
25. FIGURE 2 from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
26. Data from The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
27. The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
28. Metastatic Prostate Cancer
29. Data from Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
30. Supplementary Table 7 from Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
31. Supplementary Figures 1 - 6 from Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
32. Supplementary Table 1 from Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
33. Supplementary Table 3 from Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
34. Supplementary Table Legends from Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
35. Supplementary Table 2 from Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
36. Supplementary Table 6 from Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
37. Supplementary Table 4 from Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
38. Supplementary Table 5 from Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine
39. Supplementary Data from A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
40. TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC
41. Long-term taxane exposure and transdifferentiation of prostate cancer in vitro.
42. Pathological Assessment of Prostate Cancer
43. Experimental in vitro, ex vivo and in vivo models in prostate cancer research
44. Metastatic Prostate Cancer
45. The Gene Expression Landscape of Prostate Cancer BM Reveals Close Interaction with the Bone Microenvironment
46. Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarker
47. Targeting cyclin-dependent kinase 7—association between CDK7 and pMED1 expression in prostate cancer tissue
48. Bone biopsy protocol for advanced prostate cancer in the era of precision medicine
49. Histone Demethylase KDM5C Drives Prostate Cancer Progression by Promoting EMT
50. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.